TrialFrontiers in immunology2021

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies.

Elena E Perez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.